中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

7 records (took 0.021 seconds)

    Antibodies of the Class IGG4
    1.
    发明申请
    Antibodies of the Class IGG4 审中-公开

    公开(公告)号：US20200157204A1

    公开(公告)日：2020-05-21

    申请号：US16717671

    申请日：2019-12-17

    Applicant: UCB PHARMA S.A.

    Inventor： David Paul Humphreys ,  Ralph Adams ,  James Heads ,  Shirley Jane Peters

    IPC: C07K16/24 ,  A61K39/395 ,  C07K16/00

    Abstract: The present invention provides an antibody of the class IgG4 comprising at least one heavy chain which comprises a CH1 domain and a hinge region, wherein in each heavy chain: a. the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b. one or more of the amino acids positioned in the upper hinge region is substituted with cysteine.

    Method for Producing Protein
    3.
    发明申请
    Method for Producing Protein 有权
    生产蛋白质的方法

    公开(公告)号：US20150025128A1

    公开(公告)日：2015-01-22

    申请号：US14451975

    申请日：2014-08-05

    Applicant: UCB PHARMA S.A.

    Inventor： Katharine Lacy Cain ,  Shirley Jane Peters ,  Paul Edward Stephens

    IPC: C12P21/00

    CPC classification number: C12P21/00 ,  C07K14/47 ,  C07K16/00 ,  C07K16/18 ,  C07K16/40 ,  C12N9/0004 ,  C12P21/02 ,  Y02P20/52

    Abstract: The present invention relates to a recombinant host cell, wherein the cell is modified to increase the expression levels of Ero1 and XBP1 relative to the expression levels of Ero1 and XBP1 in an unmodified cell. The present invention also relates to a method of producing a recombinant protein of interest comprising expressing the recombinant protein of interest in the recombinant host cell.

    Abstract translation: 本发明涉及重组宿主细胞，其中修饰细胞以相对于未修饰的细胞中Ero1和XBP1的表达水平增加Ero1和XBP1的表达水平。 本发明还涉及生产重组蛋白质的方法，包括在重组宿主细胞中表达重组蛋白质。

    Sequence asymmetric modified IgG4 bispecific antibodies
    5.
    发明授权
    Sequence asymmetric modified IgG4 bispecific antibodies 有权

    公开(公告)号：US09902768B2

    公开(公告)日：2018-02-27

    申请号：US14380310

    申请日：2013-02-22

    Applicant: UCB Pharma S.A.

    Inventor： David Paul Humphreys ,  Shirley Jane Peters

    IPC: C07K16/24 ,  C07K16/00 ,  C07K16/46

    CPC classification number: C07K16/24 ,  C07K16/00 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/94

    Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterized in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.

    Sequence Symmetric Modified IgG4 Bispecific Antibodies
    6.
    发明申请
    Sequence Symmetric Modified IgG4 Bispecific Antibodies 审中-公开
    序列对称修饰的IgG4双特异性抗体

    公开(公告)号：US20150018529A1

    公开(公告)日：2015-01-15

    申请号：US14380309

    申请日：2013-02-22

    Applicant: UCB Pharma S.A.

    Inventor： David Paul Humphreys ,  Shirley Jane Peters

    IPC: C07K16/46

    CPC classification number: C07K16/468 ,  C07K16/00 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/522 ,  C07K2317/53

    Abstract: The present disclosure relates to a symmetric bispecific antibody of the class IgG4 comprising two heavy chains which each comprise a variable domain, CH1 domain and a hinge region, wherein in each heavy chain: the cysteine in the CH1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.

    Abstract translation: 本公开涉及类IgG4的对称双特异性抗体，其包含两个重链，每个重链各自包含可变结构域，CH1结构域和铰链区，其中在每个重链中：形成链间二硫键的CH1结构域中的半胱氨酸 与轻链中的半胱氨酸键合被另一个氨基酸取代; 并且任选地位于上部铰链区域中的一个或多个氨基酸被半胱氨酸取代，其中每个重链的恒定区序列相似或相同，并且每个重链中的可变区不同，包含其的制剂， 使用上述各项进行治疗和制备所述抗体和制剂的方法。

    Sequence Asymmetric Modified IgG4 Bispecific Antibodies
    7.
    发明申请
    Sequence Asymmetric Modified IgG4 Bispecific Antibodies 有权
    序列不对称修饰的IgG4双特异性抗体

    公开(公告)号：US20150017169A1

    公开(公告)日：2015-01-15

    申请号：US14380310

    申请日：2013-02-22

    Applicant: UCB Pharma S.A.

    Inventor： David Paul Humphreys ,  Shirley Jane Peters

    IPC: C07K16/24 ,  C07K16/46

    CPC classification number: C07K16/24 ,  C07K16/00 ,  C07K16/468 ,  C07K2317/31 ,  C07K2317/51 ,  C07K2317/522 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/94

    Abstract: The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a CH1 domain, wherein a first heavy chain or fragment thereof is a class IgG4 and has: a the inter-chain cysteine at position 127, numbered according to the Kabat numbering system, in the CH1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.

    Abstract translation: 本公开提供了包含两个重链或重链片段的不对称混合抗体，其各自包含至少一个可变区，铰链区和CH1结构域，其中第一重链或其片段是IgG4类，并且具有： 在CH1结构域中根据Kabat编号系统编号的位置127处的链半胱氨酸被另一个氨基酸取代; 并且b任选地一个或多个位于上部铰链区域的氨基酸被半胱氨酸取代，并且其中第二重链或其片段的特征在于部分或全部链具有与所述第一重质 至少在可变区域外的区域（例如，恒定区域），包含上述两者的治疗剂，以及用于制备抗体和制剂的方法。

Patent Agency Ranking